Innocrin Pharmaceuticals
Durham, North Carolina, United States
About Innocrin Pharmaceuticals
Innocrin discovers and develops novel oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of prostate cancer. The company offers CYP17 lyase, a validated enzyme target for the treatment of CRPC and other hormonally-driven conditions, such as breast cancer, endometriosis, or congenital adrenal hyperlplasia. Its product under pipeline is VT-464, a dual mechanism lyase-selective CYP17 inhibitor and androgen receptor (AR) antagonist that disrupts the validated biochemical pathways required for prostate cancer growth–androgen biosynthesis and AR transcriptional signaling.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $36.0M
- Funding stage: Late Stage Venture
- Last round: Series D (Apr 2015)
- Website: innocrinpharma.com
Industries & Categories
Biotechnology, Health Care, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/innocrin-pharmaceuticals-2517222 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.